Browsing Tag
HER2 ADC
1 post
Innovent Biologics advances IBI354 into Phase 3 trial for HER2-expressing platinum-resistant ovarian cancer
Discover how Innovent Biologics is advancing IBI354, a novel HER2-targeted therapy, into Phase 3 trials to transform ovarian cancer treatment.